Pearls, pitfalls, and surgical indications of the Intuity TM heart valve: A rapid deployment bioprosthesis. A systematic review of the literature. Issue 12 (20th November 2022)

• Record Type: Journal Article
• Authors: Dokollari, Aleksander; Torregrossa, Gianluca; Sicouri, Serge; Veshti, Altin; Margaryan, Rafik; Cameli, Matteo; Mandoli, Giulia Elena; Maccherini, Massimo; Montesi, Gianfranco; Cabrucci, Francesco; Coku, Lindita; Arora, Rakesh; Li, Qiao Ri; Bonacchi, Massimo; Gelsomino, Sandro
• Is Part Of: Journal of cardiac surgery. Volume 37:Issue 12(2022)
• Page Start: 5411
• Page End: 5417
• Publication Date: 2022-11-20
• Subjects: aortic valve -- echocardiography -- Intuity -- long‐term outcomes -- perceval -- rapid‐deployment -- sutured valves -- TAVR; Heart -- Surgery -- Periodicals; 617.412005
• DOI: 10.1111/jocs.17231
• Languages: English
• ISSNs: 0886-0440

Abstract

Abstract: Objectives: To highlight short‐ and long‐term clinical outcomes of the Intuity TM rapid deployment prosthesis for surgical aortic valve replacement. Methods: We reviewed on PubMed/MEDLINE, Embase, SciELO, LILACS, CCTR/CENTRAL, and Google Scholar for clinical trials, retrospective clinical studies, meta‐analysis, and gray literature. Results: Fourty‐five clinical studies with 12.714 patients were included in the analysis. Thirty‐day mortality ranged from 3.8% for Intuity and 3.9% for transcatheter aortic valve replacement (TAVR). The incidence of paravalvular leak (PVL) (Intuity 0% and TAVR 2.17%), permanent pacemaker implantation (Intuity 11.11% and TAVR 12.5%), stroke (Intuity 2.2% and TAVR 2.6%), myocardial infarction (MI) (Intuity 0% and TAVR 1%), were all higher in the TAVR group. Compared to other sutured bioprosthesis (SB), mortality ranged from 0% to 3.9% for Intuity and 0%−6.9% for SB. Long‐term cardiac mortality ranged from 0.9% to 1.55% for Intuity and 1.4%−3.3% for the Perceval valve. The incidence of PVL (Intuity 0.24%−0.7% and Perceval 0%−1%), endocarditis (Intuity 0.2%−0.7% and Perceval 1.6%−6.6%), stroke (Intuity 0.36%−1.4% and Perceval 0%−0.8%), MI (Intuity 0.07%−0.26%), and SVD (Intuity 0.12%−0.7% and Perceval 0%) were comparable. Compared to standard full sternotomy (SFS), minimally invasive surgery (MINV) mortality ranged from 0% to 4.3% for MINV and 0%−2.1% for SFS. Hospital costs outcomes ranged from $37, 187−$44, 368 for the Intuity, $69, 389 for TAVR, and $13, 543 for SB. Intuity short‐term mortality ranged between 0.9% and 12.4% while long‐term mortality ranged between 2.6% and 20%. Conclusions: This manuscript provides a 360° overview of the current rapid deployments, sutureless, and TAVR prosthesis.